Business Model Breakdown
How Purple Biotech Ltd Makes Money
PPBT
Market Cap
$6M
Profit Margin
0.0%
Employees
9
The Short Version
Purple Biotech is an oncology-focused biotech company that develops novel therapeutic candidates, primarily for hard-to-treat cancers. It operates an R&D-intensive model, aiming to advance drug candidates through pre-clinical and clinical trials. Its primary goal is to either license out successful drug candidates to larger pharmaceutical companies for further development and commercialization, or to secure strategic partnerships that provide funding and potentially lead to royalty revenues. The company's current value creation relies heavily on achieving clinical milestones and demonstrating the efficacy and safety of its pipeline assets.
Where the Revenue Comes From
Currently minimal to none; future revenue expected from licensing fees, milestone payments, and potential royalties (~100% of future revenue)
Who buys: Future licensing partners (larger pharmaceutical and biotechnology companies)
Why It Works (Competitive Advantages)
- ✔Proprietary CAPTN-3 tri-specific antibody platform technology
- ✔Clinical-stage assets (CM24, NT219) targeting specific unmet needs
Economic Moat: Narrow (Intangible Assets/IP (patents protecting drug candidates and the CAPTN-3 platform))
What Our Analysis Says
DVR Score as of April 7, 2026
Purple Biotech targets high-unmet-need oncology markets with a promising diversified pipeline, including the novel CAPTN-3 tri-specific antibody platform progressing towards IND (Q4 2026) and two Phase 2 assets (CM24, NT219) positioned for partnerships, indicating substantial TAM and significant 10x potential upon clinical success. A crucial positive development since the last analysis is the extended cash runway into H1 2027, significantly de-risking immediate dilutive financing concerns and providing vital time for pipeline advancement and partnership opportunities. While the company remains unprofitable, the improving adjusted operating loss trend and regained Nasdaq compliance are positive signals. However, high inherent clinical risk, future funding needs, and the early stage of the lead platform temper the overall score.